Document is current
Any future updates will be listed below
-
Authors
Kotikalapudi, Nagasuryaprasad https://orcid.org/0000-0003-2126-9052
Ramachandran, Deepti https://orcid.org/0000-0003-1113-1295
Vieira, Daniel https://orcid.org/0009-0004-1080-6814
Rubio, William B.
Gipson, Gregory R. https://orcid.org/0000-0002-3698-4182
Troncone, Luca https://orcid.org/0000-0002-2056-8758
Vestal, Kylie https://orcid.org/0000-0001-6421-8488
Maridas, David E.
Rosen, Vicki https://orcid.org/0000-0002-4029-1055
Yu, Paul B. https://orcid.org/0000-0003-2145-4944
Thompson, Thomas B.
Banks, Alexander S. https://orcid.org/0000-0003-1787-6925
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK107717, R01DK133948)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director
- License Information
-
More Information
Article History
Received: 17 December 2024
Accepted: 1 May 2025
First Online: 13 May 2025
Competing interests
: ASB receives research funding from Eli Lilly and Company. VR is a consultant and on the scientific advisory board for Keros Therapeutics. PBY is a co-founder, consultant, and stockholder for Keros Therapeutics. PBY is a co-founder and stockholder of Modal Therapeutics, and OrphAI Therapeutics. PBY receives research funding from Gossamer Bio, Inc., and Pfizer, Inc. ASB and TBT are consultants for Alnylam Pharmaceuticals and Keros Therapeutics. The authors have no other relevant competing interests to declare.
